Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

237 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rechallenge of afatinib for EGFR-mutated non-small cell lung cancer previously treated with osimertinib: a multicenter phase II trial protocol (REAL study).
Araki T, Kanda S, Komatsu M, Sonehara K, Tateishi K, Takada M, Kato A, Yamamoto M, Nishie K, Hama M, Agatsuma T, Kakizaki Y, Yoshiike F, Matsuo A, Chiaki T, Samizo K, Takagi Y, Yamaura M, Hanaoka M, Koizumi T. Araki T, et al. Among authors: agatsuma t. Transl Lung Cancer Res. 2023 Jun 30;12(6):1320-1327. doi: 10.21037/tlcr-23-12. Epub 2023 Jun 15. Transl Lung Cancer Res. 2023. PMID: 37425417 Free PMC article.
C-PLAN index as a prognostic factor for patients with previously untreated advanced non-small cell lung cancer who received combination immunotherapy: A multicenter retrospective study.
Sonehara K, Ozawa R, Hama M, Nozawa S, Agatsuma T, Nishie K, Kato A, Matsuo A, Araki T, Komatsu M, Tateishi K, Hanaoka M. Sonehara K, et al. Among authors: agatsuma t. Thorac Cancer. 2023 Feb;14(6):636-642. doi: 10.1111/1759-7714.14798. Epub 2023 Jan 12. Thorac Cancer. 2023. PMID: 36635979 Free PMC article.
EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: A multicenter retrospective observational study.
Araki T, Kanda S, Obara M, Agatsuma T, Kakizaki Y, Hama M, Yamamoto H, Takada M, Yamamoto M, Matsuo A, Kondo D, Komatsu M, Sonehara K, Tateishi K, Hanaoka M, Koizumi T. Araki T, et al. Among authors: agatsuma t. Respir Investig. 2024 Mar;62(2):262-268. doi: 10.1016/j.resinv.2024.01.002. Epub 2024 Jan 20. Respir Investig. 2024. PMID: 38245931 Free article.
Prognostic Value of the Geriatric Nutritional Risk Index in Previously Untreated Patients With Advanced NSCLC Treated With a Combination Therapy of Anti-PD-1/-PD-L1 Antibodies and Platinum-Based Chemotherapy: A Multicenter Retrospective Study.
Hirabayashi T, Sonehara K, Ozawa R, Hachiya T, Nozawa S, Agatsuma T, Yamamoto H, Kato A, Matsuo A, Araki T, Komatsu M, Tateishi K, Hanaoka M. Hirabayashi T, et al. Among authors: agatsuma t. Oncology. 2024 Feb 6. doi: 10.1159/000536120. Online ahead of print. Oncology. 2024. PMID: 38320539
Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data.
Terai H, Soejima K, Shimokawa A, Horinouchi H, Shimizu J, Hase T, Kanemaru R, Watanabe K, Ninomiya K, Aragane N, Yanagitani N, Sakata Y, Seike M, Fujimoto D, Kasajima M, Kubo A, Kusumoto S, Oyamada Y, Fujiwara K, Mori M, Hashimoto M, Shingyoji M, Kodani M, Sakamoto J, Agatsuma T, Kashiwabara K, Inomata M, Tachihara M, Tanaka K, Hayashihara K, Koyama N, Matsui K, Minato K, Jingu D, Sakashita H, Hara S, Naito T, Okada A, Tanahashi M, Sato Y, Asano K, Takeda T, Nakazawa K, Harada T, Shibata K, Kato T, Miyaoka E, Yoshino I, Gemma A, Mitsudomi T. Terai H, et al. Among authors: agatsuma t. JTO Clin Res Rep. 2022 Sep 1;3(11):100404. doi: 10.1016/j.jtocrr.2022.100404. eCollection 2022 Nov. JTO Clin Res Rep. 2022. PMID: 36275911 Free PMC article.
Raludotatug Deruxtecan, a CDH6-Targeting Antibody-Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models.
Suzuki H, Nagase S, Saito C, Takatsuka A, Nagata M, Honda K, Kaneda Y, Nishiya Y, Honda T, Ishizaka T, Nakamura K, Nakada T, Abe Y, Agatsuma T. Suzuki H, et al. Among authors: agatsuma t. Mol Cancer Ther. 2024 Mar 4;23(3):257-271. doi: 10.1158/1535-7163.MCT-23-0287. Mol Cancer Ther. 2024. PMID: 38205802 Free PMC article.
237 results